appendix adenocarcinoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Encorafenib + Panitumumab appendix adenocarcinoma sensitive detail...
BRAF V600E Cetuximab + Encorafenib appendix adenocarcinoma sensitive detail...
RET fusion Selpercatinib appendix adenocarcinoma sensitive detail...
MSH6 negative Pembrolizumab appendix adenocarcinoma sensitive detail...
MLH1 negative Pembrolizumab appendix adenocarcinoma sensitive detail...
MLH1 negative Nivolumab appendix adenocarcinoma sensitive detail...
MSH6 negative Nivolumab appendix adenocarcinoma sensitive detail...
MLH1 negative Ipilimumab + Nivolumab appendix adenocarcinoma sensitive detail...
MSH6 negative Ipilimumab + Nivolumab appendix adenocarcinoma sensitive detail...
MLH1 negative Dostarlimab-gxly appendix adenocarcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly appendix adenocarcinoma sensitive detail...
MLH1 negative Cemiplimab appendix adenocarcinoma sensitive detail...
MSH6 negative Cemiplimab appendix adenocarcinoma sensitive detail...
MLH1 negative Retifanlimab appendix adenocarcinoma sensitive detail...
MSH6 negative Retifanlimab appendix adenocarcinoma sensitive detail...
MLH1 negative Tislelizumab appendix adenocarcinoma sensitive detail...
MSH6 negative Tislelizumab appendix adenocarcinoma sensitive detail...
MLH1 negative Toripalimab-tpzi appendix adenocarcinoma sensitive detail...
MSH6 negative Toripalimab-tpzi appendix adenocarcinoma sensitive detail...
MLH1 negative AK105 appendix adenocarcinoma sensitive detail...
MSH6 negative AK105 appendix adenocarcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01061515 Phase I Capecitabine Bevacizumab Oxaliplatin Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Active, not recruiting USA 0
NCT02834013 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Completed USA 0
NCT03693846 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors Terminated USA 0
NCT04158349 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI) Terminated USA 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT05121038 Phase Ib/II CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) Active, not recruiting USA 0
NCT06399757 Phase Ib/II APL-5125 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors Recruiting USA 0